Clinical validation of an antibiotic-resistant bacteria global vaccine platform through the first vaccine against Klebsiella pneumoniae

VAXDYN is developing innovative vaccines targeting antimicrobial-resistant infections, starting with K-VAX for Klebsiella pneumoniae, to combat a critical global health threat.

Subsidie
€ 2.494.748
2025

Projectdetails

Introduction

VAXDYN, a Spanish biotech startup, is leading innovation with a novel vaccine platform targeting antimicrobial-resistant (AMR) infections, a critical global health threat. With projections indicating a potential cost of USD 100 trillion and over 10 million deaths by 2050 due to AMR, VAXDYN's work is of paramount importance.

Technology Focus

Their patented technology focuses on the most dangerous AMR bacteria, developing vaccines for four out of the six most urgent bacterial pathogens, which are responsible for 73% of AMR-related deaths worldwide.

Unique Vaccine Platform

VAXDYN's vaccine platform stands out for its utilization of full Outer-Membrane Protein bacterial antigens with a safe carrier cell to stimulate immunity. This unique strategy has earned approval from European regulators and prestigious backers such as the CARB-X accelerator, funded by entities including the Bill and Melinda Gates Foundation and the Wellcome Trust.

Lead Vaccine: K-VAX

The company's lead vaccine, K-VAX, targets Klebsiella pneumoniae, the third leading cause of AMR deaths, claiming 700,000 lives annually. There are no current vaccines against this pathogen, which has a mortality rate exceeding 50%.

Market Potential

VAXDYN's K-VAX aims to serve both the global elderly population and prevent neonatal sepsis in low- and middle-income countries, addressing a potential $6 billion market by 2035.

Development Progress

VAXDYN is advancing K-VAX through Phase 1A trials, supported by CARB-X and private investors.

Next Steps

The next steps involve:

  1. Phase 1B trials
  2. Phase 2 trials to determine the final formulation and efficacy, for which EIC funds are crucial.

Future Plans

Post-trials, VAXDYN plans to license K-VAX, continuing the development of its second vaccine, P-VAX, for Pseudomonas aeruginosa infections in patients with chronic respiratory conditions. This strategic move underscores VAXDYN's commitment to addressing urgent health crises and leading in the AMR vaccine domain.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.494.748
Totale projectbegroting€ 2.494.748

Tijdlijn

Startdatum1-1-2025
Einddatum31-12-2026
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • VAXDYN SLpenvoerder

Land(en)

Spain

Vergelijkbare projecten binnen EIC Accelerator

EIC Accelerator

A new cardioprotective drug for acute treatment of myocardial infarction

ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.

€ 2.499.999
EIC Accelerator

Clear, scalable and scientific framework to measure terrestrial biodiversity

3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.

€ 2.252.714
EIC Accelerator

Novel and Scalable microbial products for REgenerative agriculture

N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.

€ 2.499.999
EIC Accelerator

Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security

Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.

€ 2.499.999

Vergelijkbare projecten uit andere regelingen

ERC POC

Development of a marketable adjuvant candidate for vaccine applications

ADJUVACCINE aims to validate a synthetic platform for scalable production of optimized saponin adjuvants to enhance cost-effective vaccines and attract investment for market entry.

€ 150.000
ERC STG

Advancing Phage Therapy through Synergistic Strategies: Phage-Mediated Killing and Competitive Exclusion using Engineered Prophages

PHAGE-PRO aims to revolutionize phage therapy by utilizing engineered prophages and probiotics for rapid pathogen targeting and sustained efficacy, enhancing infection management in livestock and human medicine.

€ 1.500.000
ERC POC

PReclinical EVAluation and Investigation of Laterocidamide - A novel antibiotic from a new drug class to overcome polymyxin resistance.

Project PREVAIL aims to validate the novel antibiotic Laterocidamide (LATERO) against polymyxin-resistant Gram-negative bacteria, addressing antibiotic resistance while exploring its commercial potential.

€ 150.000
MIT Haalbaarheid

InnomABs

ImmunoPrecise Antibodies (IPA) onderzoekt de haalbaarheid van het ontwikkelen van menselijke eiwitten (biologicals) als alternatief voor antibiotica om antimicrobiële resistentie te bestrijden.

€ 14.888